A narrower efficacy result, with safety in the balance
Novartis’ remibrutinib may have a place in relapsing multiple sclerosis even if its efficacy results trail those reported for Roche’s fenebrutinib. The comparison described here points to a familiar trade-off in drug development: how much disease control a treatment offers, and what patients may have to accept in return. Remibrutinib reduced relapse rates less than fenebrutinib did in separate pivotal studies, while the source describes remibrutinib’s safety profile as cleaner. That distinction could matter to clinicians weighing treatment options, though the available figures don’t establish how the drugs would compare in a direct, head-to-head trial.
The results from the REMODEL-1 and REMODEL-2 Phase 3 trials were presented Friday at an MS conference in Toronto. Against Sanofi’s approved Aubagio, remibrutinib lowered the annualized relapse rate by 35.2% in one trial and 31.2% in the other. Those are relative reductions against the comparator, not statements that a given percentage of patients avoided relapse. The difference matters: a trial’s headline percentage can sound more definitive than the underlying measure, which describes the rate of events across a study population.
What the relapse figures say
Annualized relapse rate is a way to summarize how often relapses occur across participants over time. It lets researchers compare treatment groups even when participants have different lengths of follow-up, but it doesn’t translate neatly into a prediction for any one person. A reduction in the rate can be meaningful at the group level while leaving patients and clinicians with questions about individual benefit, side effects, and how the treatment fits alongside other options.
Heinz Wiendl, a neurologist at the University of Freiburg, said the remibrutinib results amount to roughly one relapse every 13 years. That framing gives readers a more intuitive sense of the reported effect, but it shouldn’t be mistaken for a guarantee that an individual patient will go that long without a relapse. Trial averages compress variation among participants into a single measure. The practical experience of a person taking a drug can differ from that summary.
Here's the thing: neither percentage tells the full story by itself. The results are against Aubagio, so they show how remibrutinib performed relative to that approved treatment in the trials. They don’t, on the information provided here, establish how remibrutinib would perform against every available MS therapy or how its results compare with fenebrutinib under identical study conditions. Cross-trial comparisons can help frame a competitive picture, but differences in study design and participants can limit what those comparisons prove.
Why safety may change the competition
Roche’s fenebrutinib cut relapse rates by more than 50% against Aubagio in its pivotal studies, a larger reported reduction than remibrutinib’s. That gives fenebrutinib a clear efficacy advantage on the figures presented. Yet treatment decisions aren’t made on efficacy alone. If remibrutinib’s cleaner safety profile holds up under closer examination, some clinicians may see a smaller reduction in relapses as acceptable in exchange for a more favorable balance of benefits and risks.
This is more significant than it looks, but the safety claim needs careful handling. “Cleaner” is a comparative description, and the source doesn’t specify which adverse events, measurements, or patient groups underpin it. Without those details, readers can’t judge the size of the difference or whether it would affect treatment choices broadly. A safety profile is built from evidence across a trial; it isn’t a single attribute that can be separated from dose, duration, and the people enrolled.
And yet, the contrast could shape how the two drugs are discussed. A therapy with stronger relapse reduction may appeal to patients and clinicians focused on maximizing disease control. A treatment with a more favorable safety profile may be attractive where tolerability or concern about adverse effects carries greater weight. Those are general considerations, not a claim that either drug is right for a particular patient. The details behind the safety comparison will matter as much as the summary label.
Reading across separate trials
Comparing medicines tested in separate studies is common in early assessments of a crowded treatment category, but it has limits. Even when trials use the same comparator, the patient populations, follow-up periods, and other design choices may differ. Those differences can affect measured outcomes. The figures in the source support a broad observation—fenebrutinib’s reported relapse-rate reductions were larger, while remibrutinib is described as having a cleaner safety profile—but they don’t support a precise ranking of the drugs across every measure.
(And this is the part most people overlook.) A market opening isn’t the same thing as a settled clinical preference. The reported data may give Novartis a basis for arguing that remibrutinib deserves consideration despite a smaller efficacy gain, but the source doesn’t establish how doctors will prescribe it or how patients will respond. The balance could look different once the full trial results, including the underlying safety findings, are examined alongside other treatment considerations.
What to watch next
For readers following MS drug development, the central question is whether remibrutinib’s safety advantage is specific and substantial enough to offset its smaller reported reduction in relapses. The trial results create that question; the brief account here doesn’t answer it. More detail on the adverse events and the way the studies measured them would help clarify what “cleaner” means in practice. So would a fuller view of the trials’ methods and participant groups.
If you're working in this space, keep the comparison in proportion: the available figures suggest a possible competitive trade-off, not a final verdict. Novartis has results showing reductions of 35.2% and 31.2% versus Aubagio, while Roche’s fenebrutinib cut rates by more than 50% in its pivotal studies. The distinction may influence how each drug is positioned, but the evidence described here leaves important questions about comparative safety and real-world choice unanswered.
A promising contrast. Not a direct contest.